The abstract is read at the publisher; the summary is JClub's.
Fecal microbiota transplantation (FMT) is being evaluated as a way to improve immune checkpoint inhibitor (ICI) outcomes and reduce intestinal toxicity, but clinical responses remain inconsistent.
- Why it matters: ICIs face resistance and immune-related intestinal side effects, and current microbiome remodeling signals do not reliably forecast who benefits.
- What they did: This review critically integrates clinical, ecological, and mechanistic evidence, focusing on donor–recipient interactions, microbial engraftment and function, host immunity, and tumor context within the Gut-Tumor Axis.
- The result: It outlines how multi-omics and computational modeling could enable more predictable, precise microbiome interventions, while highlighting that existing evidence is fragmented and not yet fully integrated.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.